Recrutamento encerrado
FASE
Número Europeu 2019-003618-15
ARAMIS ROS
An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies
Detalhes
Destaques